FY2024 Earnings Forecast for GYRE Issued By Noble Financial

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Stock analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. Noble Financial analyst R. Leboyer forecasts that the company will earn $0.17 per share for the year. Noble Financial currently has a “Outperform” rating on the stock. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.17 EPS, FY2027 earnings at $1.72 EPS and FY2028 earnings at $2.90 EPS.

Gyre Therapeutics Price Performance

Shares of Gyre Therapeutics stock opened at $11.96 on Thursday. Gyre Therapeutics has a 12-month low of $8.26 and a 12-month high of $19.96. The company’s fifty day simple moving average is $11.24 and its two-hundred day simple moving average is $12.32.

Insider Activity

In related news, President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now directly owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 36,054 shares of company stock valued at $406,537. Corporate insiders own 19.52% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Several large investors have recently bought and sold shares of the company. FMR LLC purchased a new position in shares of Gyre Therapeutics in the 3rd quarter valued at approximately $47,000. Wells Fargo & Company MN raised its holdings in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after purchasing an additional 913 shares in the last quarter. Bank of America Corp DE lifted its position in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after buying an additional 1,996 shares during the period. Barclays PLC boosted its holdings in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after buying an additional 1,389 shares during the period. 23.99% of the stock is owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.